Cortex To Resume CX717 Alzheimer Study, Initiate ADHD Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Announcement comes after FDA approves a study protocol with higher doses of the Ampakine compound.
You may also be interested in...
Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.
Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.
Cortex’ Clinical Hold On CX717 Lifted By FDA
The company may resume clinical trials of the compound, which it has studied for Alzheimer's disease and attention deficit/hyperactivity disorder.